Header Logo

Connection

CHING-WEI DAVID TZENG to Alanine Transaminase

Back to Details
This is a "connection" page, showing publications CHING-WEI DAVID TZENG has written about Alanine Transaminase.
CHING-WEI DAVID TZENG
Connection Strength
0.049
Alanine Transaminase
  1. Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial. Lancet Gastroenterol Hepatol. 2022 03; 7(3):208-218.
    View in: PubMed
    Score: 0.049
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.